Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia-Nationwide real life data

P. Belohlavkova, D. Zackova, H. Klamova, E. Faber, M. Karas, L. Stejskal, E. Cmunt, O. Cerna, I. Jeziskova, K. Machova Polakova, P. Zak, T. Jurkova, M. Chrapava, J. Mayer

. 2024 ; 13 (17) : e70158. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019034

Grantová podpora
LX22NPO5102 The project National Institute for Cancer Research The project National Institute for Cancer Research
00179906 DRO and the Cooperatio Program

BACKGROUND: To evaluate the outcomes of first-line imatinib versus nilotinib treatment for chronic myeloid leukemia in the chronic phase (CML-CP) in real-world clinical practice. METHODS: A propensity score analysis was performed to eliminate imbalances between the treatment groups. In the analysis, 163 patients in the nilotinib group and 163 patients in the matched imatinib group were retrospectively evaluated. RESULTS: Nilotinib-treated patients achieved complete cytogenetic response (CCyR) and major molecular response more rapidly than imatinib-treated patients. However, there was no significant difference in 5-year overall survival (OS) or progression-free survival (PFS) between the two groups (OS: 94.3% vs. 90.5%, p = 0.602; PFS: 92.9% vs. 88.0%, p = 0.614). Nilotinib-treated patients had a higher failure-free survival (FFS) and event-free survival (EFS) than imatinib-treated patients (FFS: 71.7% vs. 54.3%, p = 0.040; EFS: 71.7% vs. 53.5%, p = 0.025). CONCLUSIONS: This retrospective analysis from clinical practice did not confirm any benefit of frontline nilotinib treatment for OS and PFS; however, it did demonstrate higher FFS and EFS in the nilotinib cohort.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019034
003      
CZ-PrNML
005      
20241024111151.0
007      
ta
008      
241015s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cam4.70158 $2 doi
035    __
$a (PubMed)39267544
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Belohlavkova, Petra $u 4th Department of Internal Medicine and Haematology, University Hospital Hradec Kralove and Charles University, Prague, Czech Republic $1 https://orcid.org/0000000187287443
245    10
$a Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia-Nationwide real life data / $c P. Belohlavkova, D. Zackova, H. Klamova, E. Faber, M. Karas, L. Stejskal, E. Cmunt, O. Cerna, I. Jeziskova, K. Machova Polakova, P. Zak, T. Jurkova, M. Chrapava, J. Mayer
520    9_
$a BACKGROUND: To evaluate the outcomes of first-line imatinib versus nilotinib treatment for chronic myeloid leukemia in the chronic phase (CML-CP) in real-world clinical practice. METHODS: A propensity score analysis was performed to eliminate imbalances between the treatment groups. In the analysis, 163 patients in the nilotinib group and 163 patients in the matched imatinib group were retrospectively evaluated. RESULTS: Nilotinib-treated patients achieved complete cytogenetic response (CCyR) and major molecular response more rapidly than imatinib-treated patients. However, there was no significant difference in 5-year overall survival (OS) or progression-free survival (PFS) between the two groups (OS: 94.3% vs. 90.5%, p = 0.602; PFS: 92.9% vs. 88.0%, p = 0.614). Nilotinib-treated patients had a higher failure-free survival (FFS) and event-free survival (EFS) than imatinib-treated patients (FFS: 71.7% vs. 54.3%, p = 0.040; EFS: 71.7% vs. 53.5%, p = 0.025). CONCLUSIONS: This retrospective analysis from clinical practice did not confirm any benefit of frontline nilotinib treatment for OS and PFS; however, it did demonstrate higher FFS and EFS in the nilotinib cohort.
650    _2
$a lidé $7 D006801
650    12
$a imatinib mesylát $x terapeutické užití $x škodlivé účinky $7 D000068877
650    12
$a pyrimidiny $x terapeutické užití $x škodlivé účinky $7 D011743
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a retrospektivní studie $7 D012189
650    12
$a chronická myeloidní leukemie $x farmakoterapie $x mortalita $7 D015464
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a výsledek terapie $7 D016896
650    _2
$a protinádorové látky $x terapeutické užití $x škodlivé účinky $7 D000970
650    _2
$a inhibitory proteinkinas $x terapeutické užití $x škodlivé účinky $7 D047428
650    _2
$a tendenční skóre $7 D057216
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zackova, Daniela $u Department of Internal Medicine-Haematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000198028148 $7 xx0074334
700    1_
$a Klamova, Hana $u Institute of Haematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Faber, Edgar $u Department of Haemato-oncology, University Hospital Olomouc and Palacky University, Olomouc, Czech Republic
700    1_
$a Karas, Michal $u Department of Haemato-oncology, University Hospital Plzen and Charles University, Plzen, Czech Republic
700    1_
$a Stejskal, Lukas $u Department of Haemato-oncology, University Hospital Ostrava and Ostrava University, Ostrava, Czech Republic
700    1_
$a Cmunt, Eduard $u 1st Department of Internal Medicine-Haematology, General University Hospital and Charles University, Prague, Czech Republic
700    1_
$a Cerna, Olga $u Department of Internal Medicine-Haematology, University Hospital Kralovske Vinohrady and Charles University, Prague, Czech Republic
700    1_
$a Jeziskova, Ivana $u Department of Internal Medicine-Haematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
700    1_
$a Machova Polakova, Katerina $u Institute of Haematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Zak, Pavel $u 4th Department of Internal Medicine and Haematology, University Hospital Hradec Kralove and Charles University, Prague, Czech Republic
700    1_
$a Jurkova, Tereza $u Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
700    1_
$a Chrapava, Marika $u Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
700    1_
$a Mayer, Jiri $u Department of Internal Medicine-Haematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic
773    0_
$w MED00181704 $t Cancer medicine $x 2045-7634 $g Roč. 13, č. 17 (2024), s. e70158
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39267544 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111145 $b ABA008
999    __
$a ok $b bmc $g 2201700 $s 1231007
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 13 $c 17 $d e70158 $e - $i 2045-7634 $m Cancer medicine $n Cancer Med $x MED00181704
GRA    __
$a LX22NPO5102 $p The project National Institute for Cancer Research The project National Institute for Cancer Research
GRA    __
$a 00179906 $p DRO and the Cooperatio Program
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace